Finerenone Oral Tablet + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplant; Complications
Conditions
Kidney Transplant; Complications
Trial Timeline
Apr 23, 2024 → Sep 30, 2027
NCT ID
NCT06059664About Finerenone Oral Tablet + Placebo
Finerenone Oral Tablet + Placebo is a phase 2 stage product being developed by Bayer for Kidney Transplant; Complications. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06059664. Target conditions include Kidney Transplant; Complications.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06059664 | Phase 2 | Recruiting |
Competing Products
20 competing products in Kidney Transplant; Complications